http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2012108439-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-36 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-36 |
| filingDate | 2010-09-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2012108439-A |
| titleOfInvention | METHODS FOR TREATING TUMORS OF THE BRAIN |
| abstract | 1. The use of sodium meta arsenite for the manufacture of a medicament for the treatment of brain tumors in humans, in which sodium meta arsenite crosses the blood-brain barrier. 2. The use according to claim 1, in which the formulation of the drug is developed taking into account oral administration. The use according to claim 1, in which the formulation of the drug is developed taking into account the introduction of a dose of sodium meta arsenite from 2.5 mg to 20 mg. The use according to claim 1, wherein the brain tumor is resistant to treatment with at least one chemotherapeutic substance. The use according to claim 1, wherein the brain tumor is oligodendroglioma, oligoastrocytoma, astrocytoma, medulloblastoma, meningioma, schwannoma, hemangioblastoma or hemangiocytoma. The use according to claim 1, in which the formulation of the drug is developed taking into account intravenous administration. The use according to claim 1, wherein the brain tumor is completely or partially removed surgically. A kit consisting of one or more dosage units of sodium meta arsenite, the formulation of which is developed for oral or intravenous administration, as well as one or more dosage units of a chemotherapeutic substance for the treatment of brain tumors, except for sodium meta arsenite, the formulation of which is developed for oral or intravenous administration. . The kit of claim 8, wherein the chemotherapeutic agent for treating a brain tumor is selected from alkylating agents, antifolates, and topoisomerases. |
| priorityDate | 2009-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451890815 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443495 |
Total number of triples: 15.